Beta Thalassemia Transfusion Dependent Clinical Trial
Official title:
Multicenter, Open Label, Prospective Study to Evaluate the Efficacy and Safety of Deferasirox 30 mg/kg/Day for 52 Weeks, in Transfusion-dependent Beta-thalassemic Patients With Cardiac MRI T2* < 20 Msec
This study will assess the safety and efficacy of deferasirox in patients with cardiac MRI T2* < 20 msec.
n/a
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment